Recurrent Mantle Cell Lymphoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +9 more
2022-04-07
Apr 7, 2022
C
Active, not recruiting
  • B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +12 more
  • Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
  • +4 more
  • Duarte, California
    City of Hope Comprehensive Cancer Center
2022-03-29
Mar 29, 2022
N
Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +3 more
  • Bronx, New York
  • +3 more
2022-04-05
Apr 5, 2022
N
Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Chicago, Illinois
  • +2 more
2022-04-05
Apr 5, 2022
M
Terminated
  • Central Nervous System Lymphoma
  • +6 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-30
Mar 30, 2022
C
Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +4 more
  • Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
2022-03-28
Mar 28, 2022
F
Terminated
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +12 more
  • Laboratory Biomarker Analysis
  • ROR1 CAR-specific Autologous T-Lymphocytes
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-07
Mar 7, 2022
U
Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +17 more
  • Nivolumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-02-28
Feb 28, 2022
Y
Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2022-02-23
Feb 23, 2022
M
Withdrawn
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-23
Feb 23, 2022
C
Not yet recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Duarte, California
  • +1 more
2022-03-07
Mar 7, 2022
N
Suspended
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +25 more
  • Birmingham, Alabama
  • +23 more
2022-03-05
Mar 5, 2022
C
Active, not recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia
  • +125 more
  • tetanus-CMV fusion peptide vaccine
  • laboratory biomarker analysis
  • Duarte, California
    City of Hope Medical Center
2022-02-28
Feb 28, 2022
C
Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CpG-STAT3 siRNA CAS3/SS3
  • Radiation Therapy
  • Duarte, California
    City of Hope Medical Center
2022-02-28
Feb 28, 2022
J
Active, not recruiting
  • Prolymphocytic Leukemia
  • +4 more
  • Columbus, Ohio
  • +1 more
2022-02-24
Feb 24, 2022
F
Completed
  • CD19-Positive Neoplastic Cells Present
  • +12 more
  • Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-02-08
Feb 8, 2022
C
Active, not recruiting
  • Adult Grade III Lymphomatoid Granulomatosis
  • +23 more
  • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
2022-02-16
Feb 16, 2022
N
Active, not recruiting
  • Recurrent Mantle Cell Lymphoma
  • Saint Louis, Missouri
  • +3 more
2022-02-12
Feb 12, 2022
M
Active, not recruiting
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +20 more
  • Scottsdale, Arizona
  • +1 more
2022-02-03
Feb 3, 2022
F
Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-01-24
Jan 24, 2022
F
Terminated
  • Acute Biphenotypic Leukemia
  • +29 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-01-24
Jan 24, 2022
C
Completed
  • Contiguous Stage II Mantle Cell Lymphoma
  • +5 more
  • Duarte, California
  • +1 more
2022-01-12
Jan 12, 2022
M
Active, not recruiting
  • CCND1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-01-11
Jan 11, 2022
B
Recruiting
  • Diffuse Large B-Cell Lymphoma
  • +14 more
  • La Jolla, California
  • +1 more
2022-01-10
Jan 10, 2022
O
Completed
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Portland, Oregon
    OHSU Knight Cancer Institute
2021-12-10
Dec 10, 2021